Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03708900 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
A Phase 2 study of Cushing Syndrome, sponsored by Recordati Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 15
- Study locations
NCT03708900 is a Phase 2 study of Cushing Syndrome that is actively recruiting participants, run by Recordati Group. The registered enrollment target is 12 participants, below the 179-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (93% lower). The trial reports 15 study locations across 8 states.
The verdict
NCT03708900, a Phase 2 study of Cushing Syndrome, is actively recruiting participants, sponsored by Recordati Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 15
- Study locations
Study Summary
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
Conditions Studied
Interventions
- DRUG LCI699
Study Locations (15)
Other
- Multiprofile Hospital for Active Treatment Sveta Marina EAD - Varna
- Hospital Necker Enfants Malades - Paris
- Robert Debre Hospital - Paris
- CHU Bicetre APHP Paris Saclay - Paris
- Ospedale Bambino Gesu - Roma
- University Clinical Center Ljubljana - Ljubljana
- Alder Hey Childrens NHS Foundation Trust - Liverpool
- The Royal London Childrens Hospital - London
California
- University of California San Francisco UCSF - San Francisco
Florida
- ABMED Clinical Research Corp - Cape Coral
Illinois
- Ann & Robert H. Lurie Children's Hospital - Chicago
Maryland
- National Institute of Child Health and Human Development - Bethesda
Texas
- Texas Valley Clinical Research - Weslaco
Brussels Capital
- UZ Brussel - Jette
PI
- Aziendal Ospedaliero Universitaria Pisana Presidio Ospedale di Cisanello - Pisa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2027-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03708900
The ClinicalTrials.gov registry entry for NCT03708900 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (93% lower). The listed sponsor is Recordati Group, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cushing Syndrome appearing as the primary indexed condition, and to 1 intervention - of which LCI699 is the first listed.
NCT03708900 reports 15 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03708900 about?
NCT03708900 is a clinical study titled "Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome". Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
What is the current status of trial NCT03708900?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-04-28. Estimated completion is 2027-07-21.
What conditions does trial NCT03708900 study?
This clinical trial studies the following conditions: Cushing Syndrome.
What interventions are being tested in trial NCT03708900?
The interventions under investigation include: LCI699 (DRUG).
Who is sponsoring clinical trial NCT03708900?
This trial is sponsored by Recordati Group, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03708900 being conducted?
This trial has 15 study locations across California, Florida, Illinois, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cushing Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
RECRUITING · Phase 2
-
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
RECRUITING · Phase 1
-
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
RECRUITING
-
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.